Ad35.CS.01 Circumsporozoite Malaria Vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

MalariaPlasmodium Falciparum Infection

Phase 1

Adenovirus Vaccine for Malaria

CompletedNCT00371189

National Institute of Allergy and Infectious Diseases (NIAID)Plasmodium Falciparum Infection

Start: 2007-01-31End: 2014-06-30Updated: 2014-09-22

Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso

CompletedNCT01018459

National Institute of Allergy and Infectious Diseases (NIAID)Malaria

Start: 2010-04-30End: 2011-12-31Updated: 2014-06-06

Related Papers

A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age

PLoS ONE2013-11-1152 citations

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

2012-08-0369 citations